US FDA approves Positrigo’s brain PET system, NeuroLF

Positrigo, a Swiss company developing nuclear medical imaging devices, has achieved a milestone with FDA clearance for its NeuroLF brain PET system. This ultra-compact device aids in diagnosing brain disorders like Alzheimer’s, brain tumors, epilepsy, and Parkinson’s disease. The NeuroLF allows for efficient brain imaging in a seated position, needing minimal space and no special room modifications.

This development comes at a crucial time, following the recent FDA approval of a new Alzheimer's therapy. Alzheimer's is the most common form of dementia, affecting about 70% of dementia patients over 60, with numbers expected to reach 139 million by 2050. Current PET scanners are large and costly, limiting their availability. The NeuroLF addresses this issue with its compact design, enhancing accessibility.

Positrigo, based in Zurich, also plans to expand into European and Asian markets. The FDA clearance is a significant step towards achieving its goal of widespread imaging accessibility.